Abbott Laboratories
ABT
$133.58
-$0.36-0.27%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -85.64% | 460.69% | 26.42% | 6.29% | -23.15% |
| Total Depreciation and Amortization | -6.32% | 0.75% | -0.50% | 0.00% | -0.98% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -51.26% | 406.84% | -17.02% | -53.62% | 26.67% |
| Change in Net Operating Assets | 87.72% | -5,604.26% | 148.96% | 78.00% | -434.78% |
| Cash from Operations | -50.59% | 6.03% | 38.01% | 91.22% | -66.26% |
| Capital Expenditure | 32.78% | -29.50% | -4.32% | -33.92% | 47.28% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -100.00% | -- | -- |
| Other Investing Activities | 109.59% | -284.21% | -148.10% | 392.59% | 60.87% |
| Cash from Investing | 45.73% | -45.79% | -31.13% | -6.59% | 48.42% |
| Total Debt Issued | 0.00% | 0.00% | -99.55% | -- | -- |
| Total Debt Repaid | -68.89% | -1,561.90% | 168.85% | 51.97% | 86.78% |
| Issuance of Common Stock | 1,048.00% | -72.83% | 607.69% | -90.30% | 294.12% |
| Repurchase of Common Stock | 11.11% | 58.06% | -24,933.33% | 98.67% | 12.74% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -7.10% | 0.21% | 0.10% | -0.42% | -7.77% |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -10.42% | -18.08% | -99.24% | 32.74% | 42.69% |
| Foreign Exchange rate Adjustments | 128.92% | -330.56% | 376.92% | 63.89% | -244.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,968.97% | -89.84% | -18.78% | 214.87% | -427.27% |